No internet connection — showing the saved version of the page.

Neurocrine Biosci…

USUSD
← to the screener

Neurocrine Biosciences Inc (US:NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
neurocrine.com
Investor relations
neurocrine.com/investors/
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
San Diego, United States
Management
Kyle W. Gano
  • Matt Abernethy · Chief Financial Officer
  • Eric Benevich · Chief Commercial Officer
  • David W. Boyer · Chief Corporate Affairs Officer
  • Samir Siddhanti · Chief Business Officer
  • Darin M. Lippoldt · Chief Legal Officer
Latest reports
annual 2026 2026 Proxy Statement
Employees
2 500
Founded
1992
IPO
1996-05-23
Shares outstanding
101.22 M as of 2026-10-26
DateSharesChange
26.10.2026101.22 M−0.4%buyback
22.07.2026101.65 M
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
100.37 M
Market cap
14.79 B USD
Insiders
1.06%
Institutions
102.84%
Industry (SIC)
Biological Products, (No Diagnostic Substances)
Legal form
XTIQ
ISIN
US64125C1099
LEI
549300FECER0XBN49756
P/E
24.6
EPS
6.74 USD
|
4.33
Graham number
42.16 USD price 294% above
ROE
20.4%
FCF
1.04 B USD
Debt
?
Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
Net income
703 M USD 12 mo.
For the 12 months to 30.09.2026 (4 quarters)
Revenue3.70 B USD
− Expenses2.81 B USD
Net income703 M USD
History by quarter
RevenueExpenses
31.12.2023: Revenue 515 M · Expenses 365 M · Operating profit 150 M · Net income 148 M31.03.2024: Revenue 515 M · Expenses 416 M · Operating profit 99.3 M · Net income 43.4 M30.06.2024: Revenue 590 M · Expenses 445 M · Operating profit 145 M · Net income 65.0 M30.09.2024: Revenue 622 M · Expenses 438 M · Operating profit 184 M · Net income 130 M31.12.2024: Revenue 628 M · Expenses 486 M · Operating profit 142 M · Net income 103 M31.03.2025: Revenue 573 M · Expenses 549 M · Operating profit 23.6 M · Net income 7.90 M30.06.2025: Revenue 688 M · Expenses 542 M · Operating profit 146 M · Net income 108 M30.09.2025: Revenue 795 M · Expenses 556 M · Operating profit 239 M · Net income 210 M31.12.2025: Revenue 806 M · Expenses 595 M · Operating profit 211 M · Net income 154 M31.03.2026: Revenue 815 M · Expenses 621 M · Operating profit 193 M · Net income 198 M30.06.2026: Revenue 959 M · Expenses 808 M · Operating profit 152 M · Net income 144 M30.09.2026: Revenue 1.12 B · Expenses 791 M · Operating profit 331 M · Net income 207 M
12.202309.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
38.29 USD · P/NAV 4.33
Balance sheet date30.09.2026
Assets5.63 B USD
− Liabilities1.75 B USD
= NAV (equity of the company's shareholders)3.88 B USD
− Goodwill501 M USD
− Intangible assets2.19 B USD
= Tangible NAV1.19 B USD
Shares101 300 000
NAV per share38.29 USD
Tangible NAV per share11.72 USD
Share price (NBIX)165.92 USD
P/NAV4.33
NAV history
Balance sheet dateNAVNAV per share
30.09.20263.88 B USD38.29 USD
30.06.20263.69 B USD36.35 USD
31.03.20263.41 B USD33.87 USD
31.12.20253.25 B USD32.50 USD
30.09.20253.00 B USD30.13 USD
30.06.20252.69 B USD27.22 USD
31.03.20252.54 B USD25.61 USD
31.12.20242.59 B USD26.05 USD
Description

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
US USA StocksNBIX primaryUSD165.92 +0.37%common stock
LSE London Stock Exchange0K6R IOBUSD169 +0.80%common stock
MI Borsa Italiana (Milan)1NBIX secondaryEUR151.7 +1.47%common stock
depositary receipt
SA B3 Sao PauloN1BI34BRL35.72 -0.22%depositary receipt

Price

Hover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
Blackrock Inc.13.49%13.71 M2026-06-30
JPMORGAN CHASE & CO6.29%6.4 M2026-06-30
Dodge & Cox Inc.5.49%5.58 M2026-06-30
Vanguard Portfolio Manag…4.89%4.97 M2026-06-30
Vanguard Capital Managem…4.47%4.55 M2026-06-30
State Street Corporation4.31%4.39 M2026-06-30
Dodge & Cox Funds-Dodge…3.9%3.96 M2026-06-30
AQR Capital Management,…3.76%3.82 M2026-06-30
iShares Trust-iShares Co…3.46%3.52 M2026-08-31
VANGUARD INDEX FUNDS-Van…3.14%3.19 M2026-06-30
Renaissance Technologies…2.3%2.34 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.27%2.3 M2026-06-30
Geode Capital Management…2.1%2.14 M2026-06-30
Two Sigma Investments, L…2.04%2.08 M2026-06-30
J.P. Morgan Mutual Fd. I…1.34%1.36 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.31%1.33 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.13%1.15 M2026-06-30
JPMorgan Trust II-JPMorg…1.1%1.12 M2026-06-30
iShares Trust-iShares Bi…0.73%739 6702026-08-31
SPDR S&P MIDCAP 400 ETF…0.72%735 3422026-08-31
GORMAN KEVIN CHARLES (Di…≈0.51%517 7972026-09-11
GANO KYLE W (Chief Execu…≈0.15%154 7282026-09-11
LYONS GARY A (Director)≈0.12%122 1412026-05-21
BENEVICH ERIC S. (Office…≈0.07%67 2972026-09-11
LIPPOLDT DARIN M (Office…≈0.06%56 7932026-09-11
RASTETTER WILLIAM H (Dir…≈0.04%43 6782026-05-21
ABERNETHY MATTHEW C (Chi…≈0.04%42 8082026-09-14
POPS RICHARD F (Director…≈0.04%37 7982026-05-21
ROBERTS EIRY WYN (Office…≈0.04%35 6402025-02-14
COOKE JULIE SMITH (Offic…≈0.02%24 0252026-09-11